JSC «Valenta Pharm», which stood at the origins of the foundation of the Association of Russian Pharmaceutical Manufacturers (ARPM), is renewing its membership in the Association since 2021. Since 2002, when ARPM was founded, there have been many changes in the Russian pharmaceutical market — the market itself has grown significantly, new Russian enterprises have appeared, international GxP standards have been introduced, the regulatory framework has been brought into line with the best world practices, innovative drugs, that were produced using modern technologies in the country, have entered the market. Much of what the creators of the ARPM thought and dreamed about almost 20 years ago has come true, but the realities and challenges of modern life require new solutions.

“The return of «Valenta» to the Association of Russian Pharmaceutical Manufacturers is an important and significant event for ARPM. We are united by a common understanding of the industry development strategy in Russia, common views on the issues on the Russian market, and, most importantly, an understanding of ways to solve them. I am sure that with the participation of «Valenta», the Association will not only become weightier, but will also be able to more effectively solve the problems facing the industry,” said Victor Dmitriev, ARPM General Director.

“The entry of «Valenta Pharm» JSC into the Association will allow us to directly participate in the development of decisions related to the development of the Russian pharmaceutical industry, to promote the introduction and protection of the principles of free and fair competition, and to improve the drug circulation market in Russia. The company’s employees will take an active part in the meetings of the Association’s working groups, initiate a discussion of topical issues for pharmaceutical manufacturers, propose solutions for implementation,” commented Alexandr Machin, General Director of «Valenta Pharm» JSC.

Reference information about JSC "Valenta Pharm"

Joint Stock Company «Valenta Pharmaceuticals» is a Russian pharmaceutical innovative company, founded in 1997 and engaged in the development, production and marketing of high quality prescription and OTC drugs.

The main task of «Valenta Pharm» is the development and production of high-quality innovative drugs intended for the prevention and treatment of diseases in such areas as: neuropsychiatry, urology, gastroenterology, colds and a number of others.

The product portfolio is represented by both innovative drugs and branded generics, including more than 90 drugs. Over 50% of products are included in the list of vital and essential medicines (VED). The company produces over 100 million packages of finished pharmaceutical products per year.

JSC «Valenta Pharm» has more than 1,300 employees with representation in 57 cities of Russia, as well as in neighboring countries: Belarus, Kyrgyzstan, Azerbaijan, Armenia, Uzbekistan and Kazakhstan.

In its activities, «Valenta Pharm» adheres to the highest international standards, implementing this approach both in the development of innovative drugs in accordance with the ICH requirements — GCP, GLP, and in the production process, in accordance with the good manufacturing practice — GMP.

Reference information about ARPM

The Association of Russian Pharmaceutical Manufacturers (ARPM) was founded in 2002. ARPM unites the leading Russian pharmaceutical companies, which account for more than 90% of drugs produced in the country, about 45% of exports, more than 75% of domestic drugs in the provision of necessary medicines program.

The activities of the Association are aimed at helping to improve the competitiveness of the domestic pharmaceutical industry and promote the integration of the domestic pharmaceutical industry into the world market while maintaining and increasing the production and financial potential of the industry’s enterprises. ARPM is a member of the Chamber of Commerce and Industry of the Russian Federation, the Russian Union of Industrialists and Entrepreneurs, and actively cooperates with specialized federal state authorities: the Ministry of Health of the Russian Federation, Federal Service for Surveillance in Healthcare (Roszdravnadzor), the Ministry of Industry and Trade of the Russian Federation, and the Committee of the State Duma of the Russian Federation for Health Protection.

ARPM representatives are members of the Council for the Development of the Pharmaceutical and Medical Industry under the Government of the Russian Federation.